These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

819 related articles for article (PubMed ID: 28289991)

  • 21. Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy.
    Aquaro GD; Positano V; Pingitore A; Strata E; Di Bella G; Formisano F; Spirito P; Lombardi M
    J Cardiovasc Magn Reson; 2010 Apr; 12(1):21. PubMed ID: 20374627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationship between the quantitative extent of late gadolinium enhancement and burden of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: A delayed contrast-enhanced magnetic resonance study.
    Weissler-Snir A; Hindieh W; Spears DA; Adler A; Rakowski H; Chan RH
    J Cardiovasc Electrophysiol; 2019 May; 30(5):651-657. PubMed ID: 30680853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of semi-automated scar quantification techniques using high-resolution, 3-dimensional late-gadolinium-enhancement magnetic resonance imaging.
    Rajchl M; Stirrat J; Goubran M; Yu J; Scholl D; Peters TM; White JA
    Int J Cardiovasc Imaging; 2015 Feb; 31(2):349-57. PubMed ID: 25307896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraindividual comparison of T1 relaxation times after gadobutrol and Gd-DTPA administration for cardiac late enhancement imaging.
    Doeblin P; Schilling R; Wagner M; Luhur R; Huppertz A; Hamm B; Taupitz M; Durmus T
    Eur J Radiol; 2014 Apr; 83(4):660-4. PubMed ID: 24433640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter, randomized, controlled, single-blind comparison phase III study to determine the efficacy and safety of gadobutrol 1.0 M versus gadopentetate dimeglumine following single injection in patients referred for contrast-enhanced MRI of the body regions or extremities.
    Kuwatsuru R; Takahashi S; Umeoka S; Sugihara R; Zeng M; Huan Y; Peng W; Ma L; Guo L; Teng G; Yao W; Tozaki M; Endo M; Kaji S; Ro T; Tae Hahn S; Chul Kang B; Nishimura H; Sugawara Y; Katakami N; Breuer J; Aitoku Y
    J Magn Reson Imaging; 2015 Feb; 41(2):404-13. PubMed ID: 24692302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of myocardial fibrosis quantification methods by cardiovascular magnetic resonance imaging for risk stratification of patients with suspected myocarditis.
    Gräni C; Eichhorn C; Bière L; Kaneko K; Murthy VL; Agarwal V; Aghayev A; Steigner M; Blankstein R; Jerosch-Herold M; Kwong RY
    J Cardiovasc Magn Reson; 2019 Feb; 21(1):14. PubMed ID: 30813942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.
    Bauner KU; Reiser MF; Huber AM
    Invest Radiol; 2009 Feb; 44(2):95-104. PubMed ID: 19077911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Cardiac Magnetic Resonance Feature Tracking (CMR-FT) Analysis for Detection of Myocardial Fibrosis in Pediatric Hypertrophic Cardiomyopathy.
    Bogarapu S; Puchalski MD; Everitt MD; Williams RV; Weng HY; Menon SC
    Pediatr Cardiol; 2016 Apr; 37(4):663-73. PubMed ID: 26833321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive evaluation of macroscopic and microscopic myocardial fibrosis by cardiac MR: intra-individual comparison of gadobutrol versus gadoterate meglumine.
    Rahsepar AA; Ghasemiesfe A; Suwa K; Dolan RS; Shehata ML; Korell MJ; Naresh NK; Markl M; Collins JD; Carr JC
    Eur Radiol; 2019 Aug; 29(8):4357-4367. PubMed ID: 30617490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of phase correction of late gadolinium enhancement images on scar signal quantification in patients with ischemic and non-ischemic cardiomyopathy.
    Stirrat J; Joncas SX; Salerno M; Drangova M; White J
    J Cardiovasc Magn Reson; 2015 Aug; 17(1):66. PubMed ID: 26248535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamic contrast-enhanced magnetic resonance imaging evaluation of VX2 carcinoma in a rabbit model: comparison of 1.0-M gadobutrol and 0.5-M gadopentetate dimeglumine.
    Chang JM; Moon WK; Cha JH; Jung EJ; Cho N; Kim SJ
    Invest Radiol; 2010 Oct; 45(10):655-61. PubMed ID: 20808238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double-dose 1.0-M gadobutrol versus standard-dose 0.5-M gadopentetate dimeglumine in revealing small hypervascular hepatocellular carcinomas.
    Kim YK; Lee YH; Kim CS; Han YM; Hwang SB
    Eur Radiol; 2008 Jan; 18(1):70-7. PubMed ID: 17404740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myocardial Fibrosis in Hypertrophic Cardiomyopathy: Volumetric Assessment of Late Enhancement Provided by Cardiac Computed Tomography.
    Langer C; Schaefer P; Lutz M; Eden M; Hohnhorst M; Harders H; Faber L; Jansen O; Both M; Frey N
    J Comput Assist Tomogr; 2015; 39(5):797-803. PubMed ID: 26125299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of cellular and extracellular pathology assessed by T1 mapping on regional contractile function in hypertrophic cardiomyopathy.
    Swoboda PP; McDiarmid AK; Erhayiem B; Law GR; Garg P; Broadbent DA; Ripley DP; Musa TA; Dobson LE; Foley JR; Fent GJ; Page SP; Greenwood JP; Plein S
    J Cardiovasc Magn Reson; 2017 Feb; 19(1):16. PubMed ID: 28215181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diffusion-weighted imaging in hypertrophic cardiomyopathy: association with high T2-weighted signal intensity in addition to late gadolinium enhancement.
    Shi RY; An DA; Chen BH; Wu R; Du L; Jiang M; Xu JR; Wu LM
    Int J Cardiovasc Imaging; 2020 Nov; 36(11):2229-2238. PubMed ID: 32666169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Registration of dynamic multiview 2D ultrasound and late gadolinium enhanced images of the heart: Application to hypertrophic cardiomyopathy characterization.
    Betancur J; Simon A; Halbert E; Tavard F; Carré F; Hernández A; Donal E; Schnell F; Garreau M
    Med Image Anal; 2016 Feb; 28():13-21. PubMed ID: 26619189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intermediate-signal-intensity late gadolinium enhancement predicts ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy.
    Appelbaum E; Maron BJ; Adabag S; Hauser TH; Lesser JR; Haas TS; Riley AB; Harrigan CJ; Delling FN; Udelson JE; Gibson CM; Manning WJ; Maron MS
    Circ Cardiovasc Imaging; 2012 Jan; 5(1):78-85. PubMed ID: 22135401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic value of gadobutrol versus gadopentetate dimeglumine in enhanced MRI of brain metastases.
    Fan B; Li M; Wang X; Xu Y; Li F; Zhang L; Jiang J; Jiang Y
    J Magn Reson Imaging; 2017 Jun; 45(6):1827-1834. PubMed ID: 27696616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Native T1-mapping for non-contrast assessment of myocardial fibrosis in patients with hypertrophic cardiomyopathy--comparison with late enhancement quantification.
    Małek ŁA; Werys K; Kłopotowski M; Śpiewak M; Miłosz-Wieczorek B; Mazurkiewicz Ł; Petryka-Mazurkiewicz J; Marczak M; Witkowski A
    Magn Reson Imaging; 2015 Jul; 33(6):718-24. PubMed ID: 25863138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contrast material for abdominal dynamic contrast-enhanced 3D MR angiography with parallel imaging: intraindividual equimolar comparison of a macrocyclic 1.0 M gadolinium chelate and a linear ionic 0.5 M gadolinium chelate.
    Hadizadeh DR; Von Falkenhausen M; Kukuk GM; Schöneseiffen K; Gieseke J; Schild HH; Willinek WA
    AJR Am J Roentgenol; 2010 Mar; 194(3):821-9. PubMed ID: 20173166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.